Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues.
- 1 July 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 82 (1) , 274-283
- https://doi.org/10.1161/01.cir.82.1.274
Abstract
Flecainide and other class IC antiarrhythmic drugs are effective in the prevention and termination of atrial fibrillation, but the mechanism of this action is unknown. To gain insights into potential cellular mechanisms, we evaluated the response of human atrial action potentials to equimolar therapeutic concentrations of flecainide and quinidine and compared this response to that of guinea pig, rabbit, and dog atria. Both compounds reduced Vmax more as activation rate increased, but flecainide was more potent than quinidine and had slower kinetics. The rate-dependence of Vmax reduction was similar for all species, but human tissue was more sensitive to the drugs tested. In contrast to changes in Vmax, drug-induced alterations in action potential duration showed opposite rate-dependence for the two drugs. Quinidine increased action potential duration to 95% repolarization (APD95) in human atria by 33 +/- 7% (mean +/- SD) at a cycle length of 1,000 msec, but this effect was reduced as cycle length decreased, to 12 +/- 4% (p less than 0.001) at a cycle length of 300 msec. Flecainide increased APD95 (by 6 +/- 3%) much less than quinidine at a cycle length of 1,000 msec, but its effect was increased by faster pacing, to 27 +/- 12% at a cycle length of 300 msec and 35 +/- 8% (p less than 0.001) at the shortest 1:1 cycle length. The rate-dependent response of APD to drugs was qualitatively similar but quantitatively different among species. Human tissue showed the greatest frequency-dependent drug effects on repolarization, followed by tissue from dogs and rabbits. Guinea pig atria showed the least (and statistically nonsignificant) rate-dependence of drug effect on APD. Drug-induced changes in refractoriness paralleled those in APD. We conclude that: 1) flecainide and quinidine both increase APD in human atrial tissue but with opposite rate-dependence, 2) the effects of flecainide to increase atrial APD and refractoriness are enhanced by the rapid rates typical of atrial fibrillation, and 3) animal tissues may differ importantly from human in both their sensitivity and rate-dependent response to antiarrhythmic drugs. The salutary response of atrial fibrillation to flecainide may be due to enhancement of drug action by the rapid atrial activation rates characteristic of this arrhythmia.This publication has 36 references indexed in Scilit:
- Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythmThe American Journal of Cardiology, 1989
- Restoration of sinus rhythm with flecainide in patients with atrial fibrillationThe American Journal of Cardiology, 1988
- Oral flecainide for prophylaxis of paroxysmal atrial fibrillationThe American Journal of Cardiology, 1988
- Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillationThe American Journal of Cardiology, 1987
- Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythmThe American Journal of Cardiology, 1986
- Theoretical characterization of ion channel blockade: Ligand binding to periodically accessible receptorsJournal of Theoretical Biology, 1986
- Effect of Antiarrhythmic Drugs on the Cycle Length-Dependent Action Potential Duration in Dog Purkinje and Ventricular Muscle FibersJournal of Cardiovascular Pharmacology, 1986
- A Classification of Antiarrhythmic Actions Reassessed After a Decade of New DrugsThe Journal of Clinical Pharmacology, 1984
- Electrophysiologic evaluation of encainide with use of monophasic action potential recordingThe American Journal of Cardiology, 1981
- A computer model of atrial fibrillationPublished by Elsevier ,1964